Time-resolved crystallography for the masses
“The Spitrobot will greatly accelerate research in enzymatic mechanisms"
Scientists from four research institutes in the Science City Hamburg Bahrenfeld have joined forces to develop a ground-breaking experimental setup. Their new Spitrobot greatly simplifies observing changes in proteins as they carry out their functions. This makes time-resolved crystallography accessible for non-specialist research groups, as samples can now be prepared in standard labs and processed by automated established high-throughput methods elsewhere. The device will accelerate fundamental research in health and disease. The team has now presented the concept behind the Spitrobot in Nature Communications.
The Spitrobot
Lea von Soosten, UKE
Left to right: Friedjof Tellkamp (MPSD), Pedram Mehrabi (UHH) and Eike C. Schulz (UKE)
Jörg Harms, MPSD
To develop future drugs and design new biotechnological applications, it is fundamental that scientists understand the changes in proteins while these are taking place. Currently, the beginning and the end of the reaction can be addressed but the many intermediate steps are usually missing from the picture. The simplest way to visualize these different steps is to take ‘snapshots’ of the protein throughout the reaction. Many such snapshots put together then produce a 3D ‘stop-motion-movie’, showing the changes in the protein structure over time from all angles.
So far, such experiments have required direct access to particle accelerators (synchrotrons and XFELs) and complex experimental setups, which are out of reach for many scientists. Therefore, researchers from Hamburg University (UHH), the Max Planck Institute for the Structure and Dynamics of Matter (MPSD), the European Molecular Biology Laboratory (EMBL) and the University Medical Center Hamburg Eppendorf (UKE) (all in Hamburg) have devised a different and far more accessible alternative – the Spitrobot.
The Spitrobot dramatically simplifies the entire sample preparation process, from the initial fixing of the protein crystals and kick-starting the reaction through to the precise cryo-trapping of the proteins at various stages of their transformation. Reactions are initiated simply by ‘spitting’ the substrate solution onto the target – a technology previously developed by the team. By vitrification of the samples (i.e. cooling them to a glass-like state) the Spitrobot uncouples sample preparation from data collection. Using industry standards ensures the convenient dispatch of the samples and their compatibility with high-throughput routines commonly available at synchrotrons and other facilities. Thus the experiment can be carried out in standard laboratories without immediate access to light sources – a major advantage to most researchers in structural biology.
Emmy Noether research group leader Pedram Mehrabi (UHH) and first author of the Nature Communications paper says: “The Spitrobot will greatly accelerate research in enzymatic mechanisms. It enables non-specialist groups to carry out experiments that could previously only be done by experts. This should lead to the much more wide-spread application of a really hard experiment.”
The Spitrobot has its technological origins at the MPSD where Mehrabi and last author Eike C. Schulz worked together with the Institute’s Scientific Support Unit led by Friedjof Tellkamp. Schulz and Mehrabi continued their work at the UKE and UHH respectively to benchmark the device and demonstrate its applicability to biotechnological and disease-related problems. They were joined in their efforts by colleagues from the EMBL Hamburg who demonstrated that changes in the protein can be observed during catalytic reactions.
“We devised the Spitrobot with the typical structural biology lab in mind. That is why we aimed for a versatile, robust and simple solution that allows users to work with large and small crystals alike and combines the simplest way of reaction initiation with the ability to cover the time-scales of the majority of enzymes. This will allow many more research groups to address a wider spectrum of questions, ranging from biotechnology to health and disease research,“ says Schulz, who now leads his own junior research group in infection research at the UKE, funded by the German Ministry for Education and Research.
Original publication
Other news from the department science
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Topic world Protein analytics
Protein analytics provides a deep insight into these complex macromolecules, their structure, function and interactions. It is essential for discovering and developing biopharmaceuticals, understanding disease mechanisms, and identifying therapeutic targets. Techniques such as mass spectrometry, Western blot and immunoassays allow researchers to characterize proteins at the molecular level, determine their concentration and identify possible modifications.
Topic world Digitalization in the laboratory
The topic world Digitalization in the lab presents innovations and trends from digital data systems (ELN, LIMS) to laboratory robots and networked devices (IoT) to AI and machine learning.
Topic world Digitalization in the laboratory
The topic world Digitalization in the lab presents innovations and trends from digital data systems (ELN, LIMS) to laboratory robots and networked devices (IoT) to AI and machine learning.
Last viewed contents
Category:Lettuce_diseases
Indivumed to study the integrity of biospecimen sampling procedures for the U.S. National Cancer Institute - Analysis of biopsy sampling procedures a prerequisite for the development of future individualized cancer therapies
Max-Planck-Institut für Psychiatrie - München, Germany
Ablynx reports positive Phase I data for its anti-RANKL nanobody
Bayer Innovation announces licensing agreement with greenovation Biotech
